Xbiome - also known as 中国第 - is a company developing a microbiome artificial intelligence (AI) drug discovery platform. It was founded in 2017 by Yan Tan. The company is headquartered in Shenzhen, China. It has received funding from several investors including Legend Capital, Gaorong Capital, and Morningside Venture Capital.
Xbiome's AI is intended to develop new therapeutics through metagenomic analysis. Xbiome is building a database of human microbiomes by taking pathogen-free fecal samples. The data are acquired from Chinese donors between the age of 18 to 28 years old. The final therapeutic products that Xbiome develop from the result of the metagenomic analysis are fecal microbiota transplantation capsules. These capsules are intended to be consumed by patients suffering from specific diseases. As of June 2020, Xbiome is doing clinical trials on capsules to treat autism and graft versus host disease. Additionally, Xbiome is also developing its own in vitro assays for microbial consorta and building animal models for in vivo testing.
Yan Tan - CEO, Xbiome, China